Past, Present, and Future Management of Localized Biliary Tract Malignancies

Siegel R.L. Miller K.D. Fuchs H.E. et al.

Cancer statistics, 2022.

CA Cancer J Clin. 72: 7-33Mosele F. Stefanovska B. Lusque A. et al.

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer.

Ann Oncol. 31: 377-386

National Comprehensive Cancer Network. Hepatobiliary Cancers.(Version 1.2022).

() ()

Gallbladder cancer: epidemiology and outcome.

Clin Epidemiol. 6: 99-109Henley S.J. Weir H.K. Jim M.A. et al.

Gallbladder Cancer Incidence and Mortality, United States 1999-2011.

Cancer Epidemiol biomarkers Prev. 24: 1319-1326Varshney S. Butturini G. Gupta R.

Incidental carcinoma of the gallbladder.

Eur J Surg Oncol. 28: 4-10Duffy A. Capanu M. Abou-Alfa G.K. et al.

Gallbladder cancer (GBC): 10-year experience at Memorial Sloan-Kettering Cancer Centre (MSKCC).

J Surg Oncol. 98: 485-489

Management of cancer gallbladder found as a surprise on a resected gallbladder specimen.

J Surg Oncol. 93: 690-698

Incidence of Cholangiocarcinoma in the USA from 2001 to 2015: A US Cancer Statistics Analysis of 50 States.

Cureus. 11: e3962Shaib Y.H. Davila J.A. McGlynn K. et al.

Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?.

J Hepatol. 40: 472-477

Adenocarcinoma of the Hepatic Duct at Its Bifurcation within the Porta Hepatis. An Unusual Tumor with Distinctive Clinical and Pathological Features.

Am J Med. 38: 241-256Sutton T.L. Walker B.S. Radu S. et al.

Degree of biliary tract violation during treatment of gallbladder adenocarcinoma is independently associated with development of peritoneal carcinomatosis.

J Surg Oncol. 124: 581-588Benson A.B. D'Angelica M.I. Abbott D.E. et al.

Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 19: 541-565Okami J. Dono K. Sakon M. et al.

Patterns of regional lymph node involvement in intrahepatic cholangiocarcinoma of the left lobe.

J Gastrointest Surg. 7: 850-856Bismuth H. Nakache R. Diamond T.

Management strategies in resection for hilar cholangiocarcinoma.

Ann Surg. 215: 31-38Aloia T.A. Jarufe N. Javle M. et al.

Gallbladder cancer: expert consensus statement.

HPB (Oxford). 17: 681-690Agarwal A.K. Kalayarasan R. Javed A. et al.

The role of staging laparoscopy in primary gall bladder cancer--an analysis of 409 patients: a prospective study to evaluate the role of staging laparoscopy in the management of gallbladder cancer.

Ann Surg. 258: 318-323Fuks D. Regimbeau J.M. Le Treut Y.P. et al.

Incidental gallbladder cancer by the AFC-GBC-2009 Study Group.

World J Surg. 35: 1887-1897Araida T. Higuchi R. Hamano M. et al.

Hepatic resection in 485 R0 pT2 and pT3 cases of advanced carcinoma of the gallbladder: results of a Japanese Society of Biliary Surgery survey--a multicenter study.

J Hepatobiliary Pancreat Surg. 16: 204-215D'Angelica M. Dalal K.M. DeMatteo R.P. et al.

Analysis of the extent of resection for adenocarcinoma of the gallbladder.

Ann Surg Oncol. 16: 806-816Maker A.V. Butte J.M. Oxenberg J. et al.

Is port site resection necessary in the surgical management of gallbladder cancer?.

Ann Surg Oncol. 19: 409-417Edge S.B.M.B. Frederick L.G.

American Joint Committee on cancer (AJCC) staging Handbook: from the AJCC cancer staging Manual.

8th edition. American Cancer Society, Cham, SwitzerlandIto H. Ito K. D'Angelica M. et al.

Accurate staging for gallbladder cancer: implications for surgical therapy and pathological assessment.

Ann Surg. 254: 320-325de Jong M.C. Nathan H. Sotiropoulos G.C. et al.

Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment.

J Clin Oncol. 29: 3140-3145Spolverato G. Yakoob M.Y. Kim Y. et al.

The Impact of Surgical Margin Status on Long-Term Outcome After Resection for Intrahepatic Cholangiocarcinoma.

Ann Surg Oncol. 22: 4020-4028

Response to the Comment on "Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis.

Ann Surg. 274: e743Zhang X.F. Xue F. Dong D.H. et al.

Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis.

Ann Surg. 274: e1187-e1195Jarnagin W.R. Fong Y. DeMatteo R.P. et al.

Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Ann Surg. 234 (): 507-517Jain V. Krishnamurthy G. Kumar H. et al.

Anatomical Basis of Routine Caudate Lobe Resections in Hilar Cholangiocarcinoma.

J Gastrointest Surg. 25: 2114-2115Wahab M.A. Sultan A.M. Salah T. et al.

Caudate lobe resection with major hepatectomy for central cholangiocarcinoma: is it of value?.

Hepatogastroenterology. 59: 321-324Birgin E. Rasbach E. Reissfelder C. et al.

A systematic review and meta-analysis of caudate lobectomy for treatment of hilar cholangiocarcinoma.

Eur J Surg Oncol. 46: 747-753Lamarca A. Barriuso J. McNamara M.G. et al.

Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.

J Hepatol. 73: 170-185Valle J.W. Kelley R.K. Nervi B. et al.

Biliary tract cancer.

Lancet. 397: 428-444Zhu A.X. Macarulla T. Javle M.M. et al.

Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.

JAMA Oncol. 7: 1669-1677Abou-Alfa G.K. Sahai V. Hollebecque A. et al.

Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.

Lancet Oncol. 21: 671-684Bekaii-Saab T.S. Valle J.W. Van Cutsem E. et al.

FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements.

Future Oncol. 16: 2385-2399Jarnagin W.R. Ruo L. Little S.A. et al.

Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies.

Cancer. 98: 1689-1700Doussot A. Gonen M. Wiggers J.K. et al.

Recurrence Patterns and Disease-Free Survival after Resection of Intrahepatic Cholangiocarcinoma: Preoperative and Postoperative Prognostic Models.

J Am Coll Surg. 223: 493-505 e2Valle J. Wasan H. Palmer D.H. et al.

Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.

N Engl J Med. 362: 1273-1281Edeline J. Benabdelghani M. Bertaut A. et al.

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.

J Clin Oncol. 37: 658-667Primrose J.N. Fox R.P. Palmer D.H. et al.

Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

Lancet Oncol. 20: 663-673Ebata T. Hirano S. Konishi M. et al.

Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.

Br J Surg. 105: 192-202Ben-Josef E. Guthrie K.A. El-Khoueiry A.B. et al.

SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

J Clin Oncol. 33: 2617-2622Saluja S.S. Nekarakanti P.K. Mishra P.K. et al.

Prospective Randomized Controlled Trial Comparing Adjuvant Chemotherapy vs. No Chemotherapy for Patients with Carcinoma of Gallbladder Undergoing Curative Resection.

J Gastrointest Surg. 26: 398-407Nakachi K. Konishi M. Ikeda M. et al.

A randomized Phase III trial of adjuvant S-1 therapy vs. observation alone in resected biliary tract cancer: Japan Clinical Oncology Group Study (JCOG1202, ASCOT).

Jpn J Clin Oncol. 48: 392-395Ikeda M. Nakachi K. Konishi M. et al.

Adjuvant S-1 versus observation in curatively resected biliary tract cancer: A phase III trial (JCOG1202: ASCOT).

J Clin Oncol. 40https://doi.org/10.1200/JCO.2022.40.4_suppl.382):382

Deutsche Krebshilfe E.V. BGCRUAG-ITGDHC, (DHCG) CCG. Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After CurativeIntent Resection of Biliary Tract Cancer (ACTICCA-1).

() ()

Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder Cancer (OPT-IN EA2197).

() ()Maithel S.K. Javle M.M. Mahipal A. et al.

NEO-GAP: A phase II single-arm prospective feasibility study of neoadjuvant gemcitabine/cisplatin/nab-paclitaxel for resectable high-risk intrahepatic cholangiocarcinoma.

J Clin Oncol. : 4097Cercek A. Boerner T. Tan B.R. et al.

Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.

JAMA Oncol. 6: 60-67

留言 (0)

沒有登入
gif